GEN Exclusives

More »

GEN News Highlights

More »
Jul 26, 2010

Daiichi Sankyo Becomes First Firm to License BioWa and Lonza’s Fucose-Free mAb Cell Line

  • BioWa and Lonza have licensed their recently launched Potelligent® CHOKS1V cell line to Daiichi Sankyo for use in the development and production of recombinant therapeutic antibodies. The firms say the research and commercial licensing deal is the first for the new cell line.

    The Potelligent CHOKS1V technology combines BioWa’s Potelligent engineered glycosylation platform with Lonza’s CHOK1SV cell line, developed using its GS Gene Expression System™. The Potelligent platform is designed to allow the creation of 100% fucose-free monoclonal antibodies, which BioWa claims increases Fc receptor binding, enhances antigen dependent cellular cytotoxicity, and lowers the effective therapeutic dose.

    The companies maintain studies have shown Potelligent antibodies display increased cytotoxicity against low-density antigens, while exhibiting higher efficacy at lower doses than conventional mAbs. A number of Potelligent antibodies are already in clinical trials.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?